Chong Kun Dang Holdings Corp. (001630.KS)
KRW 50100.0
(-0.6%)
KRW 50100.0
(-0.6%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 62.28 Billion KRW | 138.98% |
| 2022 | 13.61 Billion KRW | -63.41% |
| 2021 | 70.14 Billion KRW | -56.48% |
| 2020 | 119.4 Billion KRW | 29.03% |
| 2019 | 113.66 Billion KRW | 44.44% |
| 2018 | 77.82 Billion KRW | -16.63% |
| 2017 | 67.56 Billion KRW | 56.31% |
| 2016 | 39.72 Billion KRW | 50.43% |
| 2015 | 36.12 Billion KRW | -1.96% |
| 2014 | 38.02 Billion KRW | -90.35% |
| 2013 | 103.62 Billion KRW | 367.17% |
| 2012 | 102.15 Billion KRW | -3.77% |
| 2011 | 105.84 Billion KRW | 13.38% |
| 2010 | 91.25 Billion KRW | 40.03% |
| 2009 | 66.35 Billion KRW | 17.8% |
| 2008 | 54.46 Billion KRW | 6.24% |
| 2007 | 54.05 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 115.43 Billion KRW | 61.89% |
| 2024 Q2 | 19.44 Billion KRW | -6.33% |
| 2023 Q3 | 95.75 Billion KRW | 290.39% |
| 2023 Q2 | 24.52 Billion KRW | -20.59% |
| 2023 Q1 | 30.88 Billion KRW | 665.92% |
| 2023 Q4 | 14.83 Billion KRW | -84.51% |
| 2023 FY | - KRW | 138.98% |
| 2022 Q4 | 4.03 Billion KRW | 20.04% |
| 2022 Q1 | 15.77 Billion KRW | 122.57% |
| 2022 FY | - KRW | -63.41% |
| 2022 Q2 | 2.89 Billion KRW | -81.67% |
| 2022 Q3 | 3.35 Billion KRW | 16.16% |
| 2021 Q2 | 18.19 Billion KRW | -33.65% |
| 2021 FY | - KRW | -56.48% |
| 2021 Q4 | 7.08 Billion KRW | -61.72% |
| 2021 Q1 | 27.42 Billion KRW | -32.38% |
| 2021 Q3 | 18.51 Billion KRW | 1.75% |
| 2020 Q4 | 40.56 Billion KRW | 4.27% |
| 2020 Q2 | 41.99 Billion KRW | -0.5% |
| 2020 Q1 | 42.2 Billion KRW | 78.12% |
| 2020 FY | - KRW | 29.03% |
| 2020 Q3 | 38.9 Billion KRW | -7.37% |
| 2019 Q4 | 23.69 Billion KRW | -30.6% |
| 2019 FY | - KRW | 44.44% |
| 2019 Q1 | 40.82 Billion KRW | 102.23% |
| 2019 Q2 | 28.18 Billion KRW | -30.96% |
| 2019 Q3 | 34.14 Billion KRW | 21.14% |
| 2018 Q1 | 34.9 Billion KRW | 16.67% |
| 2018 Q2 | 24.72 Billion KRW | -29.17% |
| 2018 Q4 | 20.18 Billion KRW | -8.37% |
| 2018 Q3 | 22.03 Billion KRW | -10.88% |
| 2018 FY | - KRW | -16.63% |
| 2017 Q4 | 29.91 Billion KRW | 15.8% |
| 2017 Q2 | 20.4 Billion KRW | -30.07% |
| 2017 Q1 | 29.17 Billion KRW | 56.59% |
| 2017 FY | - KRW | 56.31% |
| 2017 Q3 | 25.83 Billion KRW | 26.6% |
| 2016 Q3 | 23.27 Billion KRW | 85.11% |
| 2016 Q1 | 12.9 Billion KRW | 24.11% |
| 2016 Q4 | 18.63 Billion KRW | -19.94% |
| 2016 FY | - KRW | 50.43% |
| 2016 Q2 | 12.57 Billion KRW | -2.54% |
| 2015 Q1 | 6.37 Billion KRW | -16.71% |
| 2015 Q4 | 10.39 Billion KRW | -14.09% |
| 2015 Q3 | 12.1 Billion KRW | -24.01% |
| 2015 Q2 | 15.92 Billion KRW | 149.79% |
| 2015 FY | - KRW | -1.96% |
| 2014 Q1 | 11.39 Billion KRW | -97.02% |
| 2014 Q4 | 7.65 Billion KRW | -17.89% |
| 2014 FY | - KRW | -90.35% |
| 2014 Q3 | 9.32 Billion KRW | -35.51% |
| 2014 Q2 | 14.45 Billion KRW | 26.79% |
| 2013 Q2 | 32.83 Billion KRW | 24.46% |
| 2013 Q3 | 32 Billion KRW | -2.51% |
| 2013 Q4 | 382.12 Billion KRW | 1093.87% |
| 2013 FY | - KRW | 367.17% |
| 2013 Q1 | 26.38 Billion KRW | 14.63% |
| 2012 Q1 | 13.87 Billion KRW | 0.0% |
| 2012 Q2 | 25.4 Billion KRW | 83.17% |
| 2012 Q3 | 30.66 Billion KRW | 20.7% |
| 2012 Q4 | 23.01 Billion KRW | -24.96% |
| 2012 FY | - KRW | -3.77% |
| 2011 Q2 | 23.34 Billion KRW | 16.67% |
| 2011 FY | - KRW | 13.38% |
| 2011 Q1 | 20.01 Billion KRW | 0.0% |
| 2011 Q3 | 25.14 Billion KRW | 7.71% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 19.7 Billion KRW | -3.38% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | - KRW | 40.03% |
| 2010 Q2 | 20.39 Billion KRW | 16.82% |
| 2010 Q1 | 17.46 Billion KRW | 0.0% |
| 2009 Q3 | 16.35 Billion KRW | 37.29% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q2 | 11.91 Billion KRW | -10.76% |
| 2009 Q1 | 13.34 Billion KRW | 0.0% |
| 2009 FY | - KRW | 17.8% |
| 2008 Q1 | 11.94 Billion KRW | 0.0% |
| 2008 Q3 | 11.64 Billion KRW | -0.95% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 11.75 Billion KRW | -1.59% |
| 2008 FY | - KRW | 6.24% |
| 2007 Q1 | 14.16 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q3 | 8.81 Billion KRW | -24.98% |
| 2007 Q2 | 11.74 Billion KRW | -17.1% |
| 2007 FY | - KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1182.008% |
| Dong-A Socio Holdings Co., Ltd. | 141.36 Billion KRW | 55.94% |
| Ildong Holdings Co., Ltd. | -64.03 Billion KRW | 197.264% |
| HANDOK Inc. | 35.06 Billion KRW | -77.617% |
| Kukje Pharma Co., Ltd. | -1.03 Billion KRW | 6108.662% |
| Yuhan Corporation | 127.43 Billion KRW | 51.124% |
| Dong-A ST Co., Ltd. | 37.52 Billion KRW | -65.998% |
| SAMSUNG PHARM. Co., LTD. | -21.68 Billion KRW | 387.189% |
| Hanmi Pharm. Co., Ltd. | 323.33 Billion KRW | 80.737% |
| Hanall Biopharma Co.,Ltd | 4.99 Billion KRW | -1148.101% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -311.981% |
| Dong Sung Bio Pharm.Co.,Ltd. | 3.42 Billion KRW | -1720.659% |
| MYUNGMOON Pharm co.,Ltd | 4.52 Billion KRW | -1276.022% |
| Hana Pharm Co., Ltd. | 35.48 Billion KRW | -75.516% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1182.008% |
| Ilsung Pharmaceuticals Co., Ltd. | -18.47 Billion KRW | 437.185% |
| REYON Pharmaceutical Co., Ltd. | 6.55 Billion KRW | -850.185% |
| Aprogen pharmaceuticals,Inc. | -49.29 Billion KRW | 226.358% |
| JW Holdings Corporation | 187.88 Billion KRW | 66.85% |
| Ildong Pharmaceutical Co., Ltd. | -51.22 Billion KRW | 221.581% |
| Chong Kun Dang Pharmaceutical Corp. | 283.62 Billion KRW | 78.04% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 30.191% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 268.032% |
| Hyundai Pharmaceutical Co., Ltd. | 13.2 Billion KRW | -371.508% |
| Samil Pharmaceutical Co.,Ltd | 11.82 Billion KRW | -426.59% |
| Jeil Pharmaceutical Co.,Ltd | 18.65 Billion KRW | -233.877% |
| Yuyu Pharma, Inc. | 4.85 Billion KRW | -1182.008% |
| Kwang Dong Pharmaceutical Co., Ltd. | 54.97 Billion KRW | -13.3% |
| Daewoong pharmaceutical Co.,Ltd | 164.91 Billion KRW | 62.232% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 30.191% |
| Yuhan Corporation | 127.43 Billion KRW | 51.124% |
| Jeil Pharma Holdings Inc | 33.47 Billion KRW | -86.057% |
| Yungjin Pharm. Co., Ltd. | 7.64 Billion KRW | -714.192% |
| Suheung Co., Ltd. | 77.02 Billion KRW | 19.141% |
| JW Pharmaceutical Corporation | 89.22 Billion KRW | 30.191% |
| Samjin Pharmaceuticals Co., Ltd. | 36.63 Billion KRW | -70.016% |
| Korea United Pharm Inc. | 70.78 Billion KRW | 12.003% |
| CKD Bio Corp. | -1.63 Billion KRW | 3920.083% |
| Daewon Pharmaceutical Co., Ltd. | 49.79 Billion KRW | -25.087% |
| Dongwha Pharm.Co.,Ltd | 32.56 Billion KRW | -91.282% |
| Whan In Pharm Co.,Ltd. | 36.81 Billion KRW | -69.203% |
| Shin Poong Pharm.Co.,Ltd. | -37.06 Billion KRW | 268.032% |
| Boryung Corporation | 114.28 Billion KRW | 45.502% |
| Bukwang Pharmaceutical Co., Ltd. | -30.56 Billion KRW | 303.755% |
| Ilyang Pharmaceutical Co.,Ltd | 15.11 Billion KRW | -311.981% |
| JW Lifescience Corporation | 50.82 Billion KRW | -22.537% |